432 related articles for article (PubMed ID: 30257347)
1. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
2. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
[TBL] [Abstract][Full Text] [Related]
3. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
4. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.
Guo M; Luo B; Pan M; Li M; Zhao F; Dou J
Int Immunopharmacol; 2020 Aug; 85():106631. PubMed ID: 32470879
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for metastatic colorectal cancer: present status and new options.
Ellebaek E; Andersen MH; Svane IM; Straten PT
Scand J Gastroenterol; 2012 Mar; 47(3):315-24. PubMed ID: 22214467
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
8. Vaccines for colorectal cancer and renal cell carcinoma.
Kabaker K; Shell K; Kaufman HL
Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277
[TBL] [Abstract][Full Text] [Related]
9. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
10. Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
Rivalland G; Loveland B; Mitchell P
Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294
[TBL] [Abstract][Full Text] [Related]
11. A review on development of MUC1-based cancer vaccine.
Gao T; Cen Q; Lei H
Biomed Pharmacother; 2020 Dec; 132():110888. PubMed ID: 33113416
[TBL] [Abstract][Full Text] [Related]
12. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
13. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.
Roulois D; Grégoire M; Fonteneau JF
Biomed Res Int; 2013; 2013():871936. PubMed ID: 23509794
[TBL] [Abstract][Full Text] [Related]
14. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
15. Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E; Hu XF; Xing PX
Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
[TBL] [Abstract][Full Text] [Related]
16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
18. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
19. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
20. Strategies used for MUC1 immunotherapy: preclinical studies.
Tang CK; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):951-62. PubMed ID: 18767945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]